CLLS vs. LXEO, KYTX, ADPT, CABA, REPL, VYGR, TCRX, EDIT, ALEC, and FATE
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), Replimune Group (REPL), Voyager Therapeutics (VYGR), TScan Therapeutics (TCRX), Editas Medicine (EDIT), Alector (ALEC), and Fate Therapeutics (FATE). These companies are all part of the "biological products, except diagnostic" industry.
Cellectis (NASDAQ:CLLS) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Lexeo Therapeutics has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexeo Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -529.81%. Cellectis' return on equity of -67.41% beat Lexeo Therapeutics' return on equity.
Cellectis received 398 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 67.84% of users gave Cellectis an outperform vote.
In the previous week, Lexeo Therapeutics had 8 more articles in the media than Cellectis. MarketBeat recorded 11 mentions for Lexeo Therapeutics and 3 mentions for Cellectis. Lexeo Therapeutics' average media sentiment score of 0.57 beat Cellectis' score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cellectis presently has a consensus price target of $8.50, indicating a potential upside of 230.74%. Lexeo Therapeutics has a consensus price target of $21.00, indicating a potential upside of 21.74%. Given Cellectis' higher possible upside, equities research analysts clearly believe Cellectis is more favorable than Lexeo Therapeutics.
Summary
Cellectis and Lexeo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
